Concept Architecture
Concept
Theoretically, Minimal Residual Disease (MRD) is the small number of malignant cells that remain in a patient after treatment and are undetectable using conventional diagnostic methods but identifiable with highly sensitive molecular or immunological techniques. It is founded on quantitative disease monitoring and serves as an indicator of treatment effectiveness and relapse risk. In health economics, Minimal Residual Disease is used as a prognostic biomarker and intermediate clinical endpoint to inform survival modelling and economic evaluations of therapies for haematological malignancies.
Mathematically, Minimal Residual Disease is quantified as the proportion or number of residual malignant cells relative to the total cell population. It is measured using sensitive laboratory techniques such as multiparameter flow cytometry, quantitative polymerase chain reaction or next-generation sequencing. Detection thresholds depend on the analytical method and are commonly expressed as one malignant cell among 10? to 10? normal cells.
In practice, Minimal Residual Disease is assessed at predefined time points during and after treatment to evaluate treatment response, estimate relapse risk and guide therapeutic decisions. Health economists use MRD status to estimate transition probabilities, progression-free survival, overall survival and long-term healthcare costs within decision models evaluating treatments for leukaemia, lymphoma and multiple myeloma.
Purpose
Used to quantify residual malignant disease following treatment, predict relapse risk and support survival modelling and health economic evaluation.
Mathematical Formulae
Primary Formula
MRD = Malignant Cells � Total Cells
where:
MRD = Minimal Residual Disease level
Supporting Formulae
MRD threshold:
MRD < 10??
or other predefined thresholds depending on the analytical method.
Log reduction:
Log Reduction = log??(Baseline Disease Burden � Current Disease Burden)
Related Mathematical Methods
- Molecular Response
- Major Molecular Response
- Deep Molecular Response
- Survival Analysis
- Kaplan-Meier Estimator
- Hazard Function
- Quantitative Polymerase Chain Reaction
- Next-Generation Sequencing
Example
Following induction therapy for acute lymphoblastic leukaemia, a patient undergoes Minimal Residual Disease assessment using flow cytometry. Residual leukaemic cells are detected at a frequency of 0.005%, equivalent to approximately one malignant cell per 20,000 normal cells. This MRD result indicates a low residual disease burden and is incorporated into a health economic model to estimate relapse risk, long-term survival and expected treatment costs.
Excel Implementation
| Function | Example Formula | Health Economics Application |
|---|---|---|
| COUNT | =COUNT(CellRange) | Count the total number of analysed cells. |
| COUNTIF | =COUNTIF(CellStatusRange,"Malignant") | Count residual malignant cells. |
| DIVIDE | =MalignantCells/TotalCells | Calculate the MRD proportion. |
| LOG10 | =LOG10(BaselineBurden/CurrentBurden) | Calculate the reduction in disease burden following treatment. |
VBA (Optional)
VBA can automate MRD calculations, classify patients according to predefined thresholds and summarise treatment response across patient cohorts.
Sources
- Br�ggemann M, Kotrova M. Minimal residual disease in adult ALL: technical aspects and implications for correct clinical interpretation.
- Campana D, Pui CH. Minimal residual disease-guided therapy in childhood acute lymphoblastic leukaemia.
- National Comprehensive Cancer Network. Clinical Practice Guidelines in Oncology.
- Briggs A, Claxton K, Sculpher M. Decision Modelling for Health Economic Evaluation. Oxford University Press.
- NICE. NICE Health Technology Evaluations: The Manual.
Related Concepts (2)
Library
Publications
1
Economic Evaluation in Clinical Trials — Glick, Doshi, Sonnad & Polsky, 2nd Edition ed., 2015 (Oxford University Press)
Practical guidance on conducting cost-effectiveness analyses alongside controlled trials, covering trial design, measurement of costs and quality-adjusted life years, handling censored and missing data, and reporting stochastic uncertainty. Volume 4 in the Handbooks in Health Economic Evaluation series.
BookView source →
Frequently Asked Questions (6)
What is minimal residual disease?
The small amount of disease still detectable using highly sensitive techniques after treatment appears, by less sensitive measures, to have achieved complete response.
Source: Campana 2010
What does minimal residual disease reveal that standard tests miss?
After treatment brings a cancer into apparent remission by standard tests, highly sensitive techniques can still detect tiny amounts of disease that ordinary measures overlook, and this is minimal residual disease. It matters because those small remaining traces often predict relapse, so its presence or absence refines the prognosis beyond what a conventional complete response conveys. Increasingly it guides whether to intensify, continue, or stop treatment. It sees what coarser tests cannot. Cross and colleagues (2015) discuss its detection.
Source: Cross et al. 2015
How is minimal residual disease detected?
Minimal residual disease is detected using highly sensitive laboratory techniques capable of identifying rare disease cells or disease-associated genetic markers, such as sensitive molecular methods detecting specific genetic sequences, or flow cytometry identifying characteristic cell markers. These methods can detect disease at levels far below what conventional microscopy or standard tests reveal. The specific technique depends on the disease and its markers. Because detecting minimal residual disease requires such sensitive methods, the level detectable and the reliability of the result depend on the technique's sensitivity and standardisation.
Source: Campana 2010
Why is minimal residual disease important?
Minimal residual disease is important because its presence after treatment, even when conventional measures indicate complete response, is strongly associated with a higher risk of relapse, while its absence indicates a deeper response and better prognosis. So minimal residual disease status refines the assessment of how completely treatment has worked and helps predict outcomes. It is increasingly used to guide treatment decisions, such as intensifying or continuing therapy when it is detectable. Because it provides prognostic and predictive information beyond standard response, minimal residual disease has become an important measure in managing several cancers.
Source: Baccarani et al. 2013
How is minimal residual disease used in treatment decisions?
Minimal residual disease is used in treatment decisions because its status after therapy helps stratify risk and guide management: persistent minimal residual disease may prompt more intensive or continued treatment to reduce relapse risk, while its absence may support less intensive approaches. Monitoring it over time can detect impending relapse early. Because minimal residual disease status relates strongly to outcome, it increasingly informs whether and how to adjust treatment, making it a tool for individualising therapy based on the depth of response beyond conventional measures.
Source: Campana 2010
What are the limitations of minimal residual disease assessment?
The limitations of minimal residual disease assessment arise because it depends on highly sensitive techniques whose detection limits, standardisation, and availability vary, so a negative result means disease is below the method's threshold rather than absent, and residual disease can still persist. Results can differ between methods and laboratories, and sampling may not capture disease everywhere. Interpreting and acting on minimal residual disease requires established links to outcomes for the specific disease. These limitations mean minimal residual disease is assessed with standardised, validated methods and interpreted in the context of the technique used.
Source: Campana 2010
Trust Record
Verified by Dr Darrin Baines
British health economist
Professional identity: darrinbaines.org
Verification date: 7 Nov 2025
Content version: 1.0.0
Canonical Identity
- Term code
- HE-ES-CO-043
Stable URI · Machine-readable · Resolvable · CC BY 4.0